Advertisement

Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains

    Published:January 06, 2023DOI:https://doi.org/10.1016/j.jval.2022.12.003
        Value Health. 2022;25(12):2028-2033.
        DOI of original article: 10.1016/j.jval.2022.04.1732
        There was an error in Table 1 of the published article in which row 6 was inadvertently omitted. The complete, corrected version of Table 1 is shown below:
        Table 1Key parameters for a cost-benefit analysis.
        No.ParameterValue
        1Economic value of a year in good health$150 000
        2Real interest rate (ie, nominal interest rate minus inflation; used to discount future costs and benefits)3%/year
        3Quality of life (assuming good health = 1.0)0.52 (while receiving dialysis therapy)
        40.75 (after transplant)
        5Percentage of costs of patients with kidney failure paid by taxpayers (federal and state)79%
        6Cost for all medical care while receiving maintenance dialysis therapy per year$114 000
        7Cost of a transplant procedure (including organ acquisition charge) per event$133 000
        8Cost of all medical care for a functioning graft (including medications) per year$34 000
        9Cost of kidney graft failure per event$82 000
        10Half-life of first kidney transplant (due to graft failure alone, not patient death)32.8 years
        11Average age at which 50% of patients with newly diagnosed kidney failure with the longest life expectancies would receive first transplants53.8 years
        Note. Sources for all parameters are detailed in Appendix Supplement 3 in Supplemental Materials found at https://doi.org/10.1016/j.jval.2022.04.1732.
        The online version of the article has been updated to reflect this change.

        Linked Article